Mesothelioma | Mesothelioma

... Genomics and Proteomics - PerkinElmer and GMU Collaborate to Identify Biomarker for Cancer Detection News Headlines Interviews Market Reports Company Focus This Weeks News This Months News Submit a Press Release PerkinElmer and GMU Collaborate to Identify Biomarker for Cancer Detection Date Posted: Thursday, March 30, 2006 Options: Print PerkinElmer, Inc.

has announced a five-year research collaboration agreement with George Mason University to develop an approach for cancer detection and risk stratification.

Scientists from both organizations will work together on the design of several new types of clinical assay platforms that utilize both the amino acid identification of a protein fragment and its specific mass to identify the biomarker.

Areas of focused research include Stage I lung, ovarian and breast cancers.

"For improved patient outcomes, new diagnostics are needed," said Robert F.

Friel, president, PerkinElmer Life and Analytical Sciences.

"We are excited to provide technology that enables proteomic researchers to identify new biomarkers that may be able to detect cancer earlier." "Collaborating with George Mason University's Center for Applied Proteomics and Molecular Medicine provides an excellent opportunity to combine the superior technology of PerkinElmer and the systems biology research approach of this great institution." The alliance initially calls for the creation of a proteomics technology to accurately measure and detect specific protei...

Read more...